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Abstract
Introduction: The cancer stem cell (CSC) hypothesis states that tumours consist of a cellular hierarchy with CSCs at
the apex driving tumour recurrence and metastasis. Hence, CSCs are potentially of profound clinical importance.
We set out to establish the clinical relevance of breast CSC markers by profiling a large cohort of breast tumours in
tissue microarrays (TMAs) using immunohistochemistry (IHC).
Methods: We included 4, 125 patients enrolled in the SEARCH population-based study with tumours represented
in TMAs and classified into molecular subtype according to a validated IHC-based five-marker scheme. IHC was
used to detect CD44/CD24, ALDH1A1, aldehyde dehydrogenase family 1 member A3 (ALDH1A3) and integrin
alpha-6 (ITGA6). A ‘Total CSC’ score representing expression of all four CSC markers was also investigated.
Association with breast cancer specific survival (BCSS) at 10 years was assessed using a Cox proportional-hazards
model. This study was complied with REMARK criteria.
Results: In ER negative cases, multivariate analysis showed that ITGA6 was an independent prognostic factor with
a time-dependent effect restricted to the first two years of follow-up (hazard ratio (HR) for 0 to 2 years follow-up,
2.4; 95% confidence interval (95% CI), 1.2 to 4.8; P = 0.009). The composite ‘Total CSC’ score carried independent
prognostic significance in ER negative cases for the first four years of follow-up (HR for 0 to 4 years follow-up, 1.3;
95% CI, 1.1 to 1.6; P = 0.006).
Conclusions: Breast CSC markers do not identify identical subpopulations in primary tumours. Both ITGA6 and a
composite Total CSC score show independent prognostic significance in ER negative disease. The use of multiple
markers to identify tumours enriched for CSCs has the greatest prognostic value. In the absence of more specific
markers, we propose that the effective translation of the CSC hypothesis into patient benefit will necessitate the
use of a panel of markers to robustly identify tumours enriched for CSCs.
Introduction
The existence of tumour initiating cells also called can-
cer stem cells (CSCs) in breast cancer has been demon-
strated by several studies [1-3]. It has been shown that
xenotransplanted cell subpopulations enriched for CSCs
can generate tumours in non-obese severe-combined
immunodeficient (NOD/SCID) mice from a fraction of
the number of unselected cells required to form
tumours. In addition, tumours resulting from the
implantation of small numbers of CSCs recapitulate the
molecular heterogeneity of the original mixed
population. The CSC hypothesis holds that since this
subpopulation of cells is exclusively able to form
tumours they underpin both disease recurrence and
metastasis [4]. Therefore, CSCs are potentially of major
clinical significance.
In order to demonstrate the functional characteristics
which define a CSC, it is necessary to isolate candidate
CSCs. This has been achieved by use of cell-surface
markers and by tagging cells which exhibit characteris-
tics associated with stemness. The combination of CD44
and CD24 first enabled Al-Hajj et al. to prospectively
isolate a CSC subpopulation of from eight of nine
patients with breast cancer [1]. After excluding non-
epithelial cells (lineage-), CD44+CD24-/low cells were
enriched by flow cytometry and subsequently implanted
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into NOD/SCID mice. The CD44+CD24-/low cells were
able to form tumours in NOD/SCID mice from fewer
cells than the mixed population with 10- to 50-fold
enrichment for this ability. The resulting xenografts
were found to exhibit the same phenotypic diversity as
the original tumours [1].
A similar paradigm for experimentation was used to
show that cell subpopulations with high aldehyde dehy-
drogenase (ALDH) activity were enriched for CSCs [3].
The ALDEFLUOR assay uses a biochemical reaction to
tag cells with high ALDH activity with cytoplasmic
fluorescence, permitting their enrichment by flow cyto-
metry. Ginestier et al. found that ALDEFLUOR-positive
normal mammary epithelial cells from reduction mam-
moplasties were enriched for sphere-forming ability and
in vivo outgrowth potential, forming 10-fold more ducts
in NOD/SCID mice. Similarly, ALDEFLUOR-positive
cells from xenografts of human breast carcinomas were
able to form tumours in NOD/SCID mice from as few
as 500 cells, whereas ALDEFLUOR-negative cells incon-
sistently formed tumours and required 50, 000 cells to
do so. Again, the tumours resulting from the implanta-
tion of ALDEFLUOR-positive cells contained both
ALDEFLUOR-positive and negative cells in proportions
similar to the original mixed population. The clinical
relevance of this finding was investigated by using
immunohistochemistry (IHC) to stain for aldehyde
dehydrogenase family 1 member A1 (ALDH1A1) in 481
primary breast carcinomas. ALDH1A1 retained indepen-
dent prognostic significance in a multivariate analysis
[3]. The ALDEFLUOR assay is designed to detect
expression of ALDH1A1 (STEMCELL Technologies
SARL, Grenoble, France) and, consistent with this,
Ginestier et al. found that ALDH1A1 expression was
restricted to the ALDEFLUOR-positive subpopulation
from normal mammary epithelial cells. However, the
identity of the aldehyde dehydrogenase isoform(s)
responsible for ALDEFLUOR-positivity in malignant
breast epithelial cells has been questioned. Marcato et
al. sought to establish whether ALDEFLUOR-positivity
in primary breast tumours and breast cancer cell-lines
related to a particular isoform(s) of ALDH or a global
increase in ALDH activity [5]. Aldehyde dehydrogenase
family 1 member A3 (ALDH1A3) not ALDH1A1, was
found to correlate most strongly with ALDEFLUOR-
positivity and, using immunofluorescence (IF) in pri-
mary tumours, was also found to correlate with metasta-
sis and tumour grade. Moreover, the knockdown of
ALDH1A3 in three breast cancer cell lines abrogated
ALDEFLUOR activity [5].
An alternative approach to the CSC problem was used
by Pece et al., who, by exploiting the quiescent nature of
normal mammary stem cells, isolated sufficient numbers
to derive a gene expression signature [2]. The lipophilic
dye PKH26 was used to isolate the most mitotically inac-
tive fraction of self-renewing epithelial cells from reduc-
tion mammoplasties. The resulting gene signature was
found to correlate with the grade of breast tumours. This
correlation was established directly by comparison with
published datasets and, indirectly, both by the prospec-
tive isolation of primary breast cancer cells using a subset
of high-ranking markers from the gene signature and by
IHC of breast tumours. By IHC and IF it was shown that
grade 3 breast tumours contained a three- to four-fold
greater proportion of cells expressing these high-ranking
markers compared to grade 1 tumours. The authors
argue that the grade of breast tumours is a function of
their CSC content [2]. Prominent amongst the markers
of the normal mammary stem cell-derived signature was
CD49f or alpha-6 integrin (ITGA6). ITGA6 is a cell-sur-
face protein which has been shown to identify adult
mouse mammary stem cells [6] and a tumorigenic subpo-
pulation in the MCF-7 breast cancer cell line [7] as well
as regulating CSCs in glioblastoma [8].
Although CD44+CD24-/low, ALDH1A1, ALDH1A3 and
ITGA6 appear to enrich for CSCs it is important to note
that this is not always the case. For example, the CD44
+CD24-/low phenotype was not successful in identifying
CSCs in one of the nine patient specimens originally
reported [1]. Similarly, Hwang-Verslues et al. found that
the expression of stem cell markers, including CD44
+CD24-/low and ALDH1A1, varied between breast cancer
cell lines and between primary tumours, and that these
markers did not universally enrich for CSCs [9]. Heteroge-
neity amongst the phenotype of CSCs and the existence of
multiple clones of cells acting as CSCs are well-established
concepts in the haematological malignancies [10]. It has
been proposed that breast CSCs may exhibit heterogeneity
between the subtypes of breast cancer in a manner analo-
gous to the haematological malignancies [11].
Although several studies have profiled CSC markers in
primary breast tumours [12-17], they have reached differ-
ent conclusions and their precise clinical significance
remains uncertain. We set out to establish the clinical rele-
vance of the CSC hypothesis in breast cancer by profiling a
large cohort of primary breast carcinomas using IHC and
tissue microarrays (TMAs). We hypothesised that the sig-
nificance of CSC markers may not be universal amongst
breast cancers but may be subtype specific. In order to
assess the relationship between subtype and CSC markers,
we have divided tumours into molecular subtypes accord-
ing to a validated panel of IHC markers and stratified all
analyses by oestrogen receptor status (ER).
Materials and methods
Study population
The SEARCH breast study was used for this work.
SEARCH is a large prospective population-based study
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of women diagnosed with breast cancer identified
through the East Anglia Cancer Registry. It includes pre-
valent cases diagnosed before the age of 55 during 1991
to 1996 and still alive in 1996 and incident cases con-
sisting of women under the age of 70 diagnosed after
1996; details of this study have been published pre-
viously [18]. A total of 4, 125 patients were included.
Data on age at diagnosis, vital status including breast
cancer-specific mortality, follow-up time, time between
diagnosis and study entry, lymph node status, histologi-
cal grade, tumour size, detection by mammographic
screening, hormone therapy and chemotherapy were
available. Details of the characteristics of the cohort are
provided in Table 1. The SEARCH (Studies of Epide-
miology and Risk Factors in Cancer Heredity) study is
approved by the Cambridgeshire 4 Research Ethics
Committee; all study participants provided written
informed consent.
Immunohistochemistry and scoring
Paraffin embedded tissue blocks containing primary
breast carcinoma were constructed as tissue microarrays
(TMAs) as previously described [19]. Each tumour was
represented by a 0.6 mm tissue core. Staining patterns
in histologically normal breast tissue were assessed from
one block. IHC was used to assay for the expression of
cancer stem-cell related and other relevant proteins as
detailed in Additional file 1. Briefly, 3 to 4 μm paraffin
sections were dewaxed in xylene and rehydrated through
graded alcohols. IHC was conducted using a BondMaX
auto-immunostainer (Leica, Bucks, UK). Bound primary
antibody was detected using a polymer-conjugated sec-
ondary antibody and staining was developed with 3-3’-
diaminobenzidine (DAB). Double-immunostaining for
detection of the CD44+CD24-/low phenotype was done
in sequence, with detection of bound mouse anti-CD24
antibody with a biotinylated secondary antibody devel-
oped with DAB and detection of bound rabbit anti-
CD44 with a polymer-conjugated secondary antibody
developed using alkaline phosphatase with fast-red as a
chromogen. Stained TMAs were viewed following digiti-
sation using the Ariol platform (Genetix Limited,
Hampshire, UK). The extent of staining was assessed
blinded to all patient and tumour characteristics. Only
membranous CD44 expression was scored while cyto-
plasmic and apical staining of lumens was scored for
CD24. For ALDH1A1 and ALDH1A3 only cytoplasmic
staining was considered and expression by stromal cells
was assessed separately. All CSC markers were scored
by a pathologist (HRA) using an Allred scoring system
accounting for both the intensity of staining (0 = none,
1 = weak, 2 = moderate, 3 = strong) and the proportion
of stained cells (0 = 0%, 1 = < 1%, 2 = 1 to 10%, 3 = 11
to 33%, 4 = 34 to 66%, 5 = > 66%) producing a sum
score of the two values (intensity + proportion = 0 to
8). The scoring system was chosen in consultation
between HRA and a senior pathologist (EP). HRA has
extensive experience in interpreting IHC in breast can-
cer TMAs, with Kappa agreement statistics of 0.81, 0.88
0.65 and 0.85 for the markers aurora kinase a (AURKA),
Trans-acting T-cell-specific transcription factor GATA-
3 (GATA3), mast/stem cell growth factor receptor kit
(c-Kit) and DNA replication licensing factor MCM2
(MCM2) respectively. The cut-offs for scoring systems
used for each antigen are detailed in Additional file 1.
In order to address whether the combination of these
Table 1 Characteristics of the SEARCH study cohort
Variable SEARCH
Mean age (range) 52.6 (24 to 73)
Mean follow-up in years (range) 8.5 (0.37 to 18.6)
Number of breast cancer deaths (%) 563 (14)
Five-year survival % 90
Categories Number Percent
Grade 1 768 19
2 1, 622 39
3 1, 020 25
Missing 715 17
Node status Negative 2, 309 56
Positive 1, 424 35
Missing 392 10
Tumour size < 2 cm 2, 208 54
2 to 4.9 cm 1, 522 37
≥5 cm 145 4
Missing 250 6
Endocrine therapy No 770 19
Yes 3, 315 80
Missing 40 1
Chemotherapy No 2, 692 65
Yes 1, 392 34
Missing 41 1
ER status Negative 772 19
Positive 2, 287 55
Missing 1, 066 26
PR status Negative 889 22
Positive 2, 194 53
Missing 1, 042 25
HER2 status Negative 2, 560 62
Positive 349 8
Missing 1, 216 29
Molecular subtype Luminal 1a 1, 631 40
Luminal 1b 215 5
Luminal 2 202 5
HER2 120 3
CBP 214 5
5NP 130 3
Missing 1, 613 39
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markers offered superior prognostic value than their use
separately, a “Total CSCs” variable was also created by
adding the four dichotomised scores together to pro-
duce five categories. However, since only five cases were
positive for all four markers, the four-marker-positive
and three-marker-positive categories were merged leav-
ing four categories (0 to 3).
Definition of molecular subtype
Tumours were classified into six molecular subtypes
using a validated IHC-based surrogate classifier accord-
ing to the expression of ER, progesterone receptor (PR),
human epidermal growth factor receptor 2 (HER2),
cytokeratin 5/6 (CK5/6) and epidermal growth factor
receptor (EGFR) [20]. Molecular subtypes were defined
as: luminal 1a (ER+ or PR+, HER2-, CK5/6- and EGFR-
), luminal 1b (ER+ or PR+, HER2-, CK5/6+ or EGFR+),
luminal 2 (ER+ or PR+, HER2+), HER2 (ER- and PR-,
HER2+), core basal phenotype (CBP) (ER- and PR-,
HER2-, CK5/6+ or EGFR+) and 5-marker negative phe-
notype (5NP) (ER-, PR-, HER2-, CK5/6-, EGFR-).
Statistical analyses
All analyses were stratified by ER status since ER
expression defines fundamentally distinct diseases within
breast cancer [20,21]. Correlations between ordinal vari-
ables were assessed using Spearman’s rank correlation.
Associations between categorical variables were assessed
using Pearson’s chi-square test or Fisher’s exact test as
appropriate. Associations with age were assessed using a
Wilcoxon rank-sum test. A log-rank test was used to
compare survival between groups in Kaplan-Meier survi-
val plots. A Cox proportional-hazards model was used
to investigate association with breast cancer-specific sur-
vival (BCSS) at 10 years follow-up, providing a hazard
ratio (HR) and 95% confidence interval (95% CI) for
each variable. Although the date of diagnosis was used
to calculate time-to-event, since SEARCH is an ongoing
study the date of study entry was used to determine
time under observation in order to adjust for the bias of
prevalent cases in a prospectively recruiting study (left-
truncation) [22]. Likelihood ratios from univariate ana-
lyses were used to decide whether to model markers as
continuous or dichotomised variables. Cut-points for
dichotomisation were informed by comparing strata
with non-expressing cases against BCSS in a Cox-pro-
portional hazards model where there was no trend to
hazard ratios, a pre-determined cut-point of > 2 was
applied. Analyses exploring associations with clinical,
molecular and survival data were also conducted using
zero as a cut-point for dichotomisation of CSC markers
in order to determine the extent to which patterns were
dependent on different cut-points. Multivariate analyses
were conducted for CSC markers significantly associated
with BCSS on univariate analysis. Multivariate models
were modified in a backward stepwise manner until the
most parsimonious fit was attained. Covariates in the
initial model included age (> 55 years), lymph node sta-
tus, grade, tumour size (< 2 cm, 2 to 4.9 cm, ≥5 cm),
endocrine therapy, adjuvant chemotherapy, PR and
HER2 status. Grade, tumour size and ‘Total CSCs’ were
modelled as continuous variables. Standard log-log plots
were used to explore compliance with the Cox propor-
tional-hazards assumption. For variables which violated
the assumption, the Cox model was extended to include
a coefficient which varied as a function of log-time,
where if the HR decreases with time the log of the coef-
ficient is < 1 and, conversely, > 1 if the HR increases
with time. The P-value of the time-varying coefficient
was also used to determine whether it was reasonable to
model a variable as time-dependent in different sub-
groups. This work complied with reporting recommen-
dations for tumour marker prognostic studies
(REMARK) criteria [23]. All analyses were conducted
using Intercooled Stata version 11.1 (StataCorp, College
Station, TX, USA). All Stata command lines used to
produce reported analyses can be made available on
request. Heatmaps and dendograms for a single ran-
domly selected imputed dataset using Allred scores were
produced using Cluster [24] and Java TreeView as pre-
viously described [25].
Missing data
The technical limitations of TMAs inevitably result in
missing data. Tumour characteristics, such as size and
morphology, tend to be correlated with the missingness
of TMA data. Hence analyses, which exclude cases with
missing data (complete case analysis (CCA)), can be
biased [26]. In order to adjust for this source of bias we
used multiple imputation (MI). MI is a method for
handling missing data which has recently been validated
for use in molecular pathology studies and been shown
to produce more precise, less biased HRs compared to
CCA [27]. MI generates a specified number of datasets
wherein instances of missing data are resolved by ran-
domly generated values which have been inferred under
a model which takes account of the rest of the data.
Subsequent analyses are performed on each imputed
dataset and the results combined in a manner which
accounts for the variability between imputed values. We
used the ice command in Stata (StataCorp) to perform
multiple imputation by chained equations [28,29] for 50
datasets across all IHC markers and relevant clinical
variables including an outcome indicator (Nelson-Aalen
estimator) to avoid inappropriate attenuation of associa-
tions [30]. Imputed data were then analysed using the
mi commands. Results of survival analyses for both
CCA and MI are presented for comparison.
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Results
CSC markers have distinct expression patterns in normal
and neoplastic breast tissue
CSC markers showed distinct patterns of staining in
normal breast tissue (Figure 1). Double-immunostaining
for CD44+CD24-/low revealed membranous CD44
expression primarily in myoepithelial cells, although
there was also some expression by luminal cells. CD24
localised to the apical surface of luminal cells and also
stained intra-luminal secretions. These patterns are con-
sistent with those previously reported [14]. In keeping
with the observations of Ginestier et al. [3], strong
ALDH1A1 expression was seen in isolated luminal cells
in terminal-ductal lobular units (TDLUs). However, in
some TDLUs ALDH1A1 expression was observed more
frequently, including occasional TDLUs where almost all
cells were positive for ALDH1A1, again in keeping with
staining patterns previously reported [14]. Myoepithelial
ALDH1A3 ITGA6
CD44/CD24
ALDH1A1
A
B
C
Figure 1 Photomicrographs of CSC marker expression in normal breast tissue. A. Double immunostaining for CD44 (red) and CD24
(brown) reveals membranous CD44 expression of myoepithelial cells and some luminal cells. CD24 stains luminal apical membranes and
secretions. B. IHC for ALDH1A1 showed different patterns, including staining of single luminal cells (right panel), of whole lobules (left panel) and
stromal cells. C. IHC for ALDH1A3 (left panel) shows weak cytoplasmic of most epithelial and mesenchymal cells. IHC for ITGA6 (right panel)
shows membranous staining of both myoepithelial and luminal cells.
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cells were also observed to express ALDH1A1 both in
ducts and, less often, in TDLUs. Nearly all stromal cells
expressed ALDH1A1. ALDH1A3 was expressed very
weakly in the cytoplasm of all mammary epithelial cells
and stromal cells. For ITGA6, membranous staining of
myoepithelial cells was predominant while staining of
luminal cells was seen less frequently.
CSC markers were expressed at different levels in
primary breast carcinomas (Figure 2 and Table 2).
ALDH1A1 expression was least frequent amongst the
CSC markers, with 59% of cases having an Allred
score of 0 compared to ALDH1A3 expression where
43% of cases were scored as 0. There were more
tumours with a maximum Allred score of 8 for the
CD44+CD24-/low phenotype than the other CSC mar-
kers (4% for CD44+CD24-/low and ≤1% for the other
CSC markers). There was a gradation of staining for
all markers, ranging from single isolated cells to small
clusters of cells to rare cases where all cells were
strongly stained (Figure 2).
ALDH1A3 ITGA6
CD44/CD24
ALDH1A1
A
B
C
Figure 2 Photomicrographs of CSC marker expression in invasive breast carcinoma. A. Membranous CD44 (red) staining and cytoplasmic
CD24 (brown) staining of carcinoma cells. Tumours contained different proportions of positive cells, including cases dominated by CD44+CD24-/
low cells (left panel) and others composed of CD24 expressing cells exclusively (right panel). B. Examples of low (left panel) and high (right panel)
ALDH1A1 expression. C. Examples of high ALDH1A3 (left panel) and high ITGA6 (right panel) expression.
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The correlations between CSC markers were stronger in
ER- than ER+ disease (Additional file 2). In ER+ disease,
ITGA6 was the only marker significantly correlated with
all other CSC markers; it was most strongly correlated
with ALDH1A3 with a Spearman’s rho of 0.16, P < 0.0001.
CD44+CD24-/low was significantly correlated with ITGA6
only (Spearman’s rho = 0.09, P = 0.0006). ALDH1A1 and
ALDH1A3 were only weakly correlated in ER+ disease
(Spearman’s rho = 0.07, P = 0.0035). By contrast, in ER-
disease all CSC markers were significantly positively corre-
lated. The correlations between markers were also gener-
ally stronger in ER- cases. ITGA6 and CD44+CD24-/low
were the most strongly correlated markers (Spearman’s
rho = 0.29, P < 0.0001) while the weakest correlations
were between ALDH1A1 and CD44+CD24-/low (Spear-
mans’s rho = 0.11, P = 0.0141) and between ALDH1A1
and ITGA6 (Spearmans’s rho = 0.11, P = 0.0176).
Association with clinical and molecular characteristics
CD44+CD24-/low and ALDH1A1 expression were signifi-
cantly associated with clinical features in analyses strati-
fied by ER status (Table 3). In ER+ disease, CD44+CD24-/
low was associated with favourable clinical parameters. Of
CD44+CD24-/low positive tumours, 33% were grade 1
whereas only 23% of CD44+CD24-/low negative tumours
were grade 1 (P = 0.006). Similarly, 68% of CD44+CD24-/
low positive tumours were node negative, compared to
60% of CD44+CD24-/low negative cases (P = 0.008). In ER
+ disease CD44+CD24-/low positive tumours were asso-
ciated with ductal morphology with 81% of CD44
+CD24-/low positive cases being ductal compared to 73%
of CD44+CD24-/low negative cases (P = 0.012). ADLH1A1
positivity was significantly associated with high tumour
grade in ER- disease only, with 43% of ALDH1A1 posi-
tive tumours being grade 3 compared to 20% of
ALDH1A1 negative tumours (P = 0.012). In contrast to
ER+ disease, the CD44+CD24-/low phenotype was asso-
ciated with higher tumour grade in ER- cases with 76% of
positive tumours being grade 3 compared to 66% of
negative cases (P = 0.020). However, as observed in ER+
disease, CD44+CD24-/low positive tumours were more
often node-negative in ER- cases also, with 64% of CD44
+CD24-/low positive tumours being node-negative com-
pared to 51% of CD44+CD24-/low negative cases (P =
0.012). In accordance with a putative CSC-marker,
ALDH1A1 was significantly associated with positive
lymph node status in ER- disease with 59% of ALDH1A1
positive cases being node positive compared to 43% of
negative cases (P = 0.036). Notably, for analyses stratified
by ER status, both ALDH1A3 and ITGA6 were not sig-
nificantly associated with any clinical features.
All CSC markers were significantly associated with
negative ER and PR status (Additional file 3). ITGA6
positive tumours showed the strongest association with
63% of cases being ER-, compared to 22% of ITGA6
negative cases (P < 0.0001). Both ALDH1A1 and
ALDH1A3 were associated with positive HER2 status
where 26% of tumours positive for either marker were
HER2 positive and 11% of negative cases were HER2
positive (P < 0.0001). By contrast, CD44+CD24-/low posi-
tive cases were significantly associated with negative
HER2 status (P = 0.025). These relationships were
reflected in the pattern of association with molecular
subtype (Table 4). The distribution of all CSC markers
Table 2 Distribution of CSC marker scores
Variable Marker
CD44
+CD24-/low
CD44-
CD24+
CD44
+CD24+
ALDH1A1 Stromal
ALDH1A1
ALDH1A3 Stromal
ALDH1A3
ITGA6 Score Total
CSCs
Allred
score
0 1, 808 (44) 814 (20) 1, 994 (48) 2, 452
(59)
1, 112 (27) 1, 763
(43)
2, 245 (54) 2, 004
(49)
0 1, 147
(28)
2 27 (1) 18 (< 1) 34 (1) 169 (4) 303 (7) 43 (1) 12 (< 1) 20 (< 1) 1 401 (10)
3 96 (2) 241 (6) 74 (2) 95 (2) 485 (12) 183 (4) 86 (2) 106 (3) 2 75 (2)
4 103 (3) 318 (8) 174 (4) 69 (2) 442 (11) 162 (4) 102 (2) 77 (2) 3 18 (< 1)
5 136 (3) 310 (8) 112 (3) 40 (1) 230 (6) 120 (3) 73 (2) 50 (1) 4 5 (< 1)
6 103 (3) 358 (9) 52 (1) 27 (1) 156 (4) 194 (5) 64 (2) 39 (1) Missing 2, 479
(60)
7 104 (3) 375 (9) 74 (2) 20 (< 1) 130 (3) 119 (3) 27 (1) 49 (1)
8 160 (4) 103 (3) 23 (1) 18 (< 1) 32 (1) 27 (1) 2 (< 1) 44 (1)
Missing 1, 588 (39) 1, 588 (39) 1, 588 (39) 1, 235
(30)
1, 235 (30) 1, 514
(37)
1, 514 (37) 1, 736
(42)
Cut-off > 4 > 3 > 2 > 4 > 2 > 6 > 3 > 4 NA
Status* Negative 2, 034 (80) 1, 073 (42) 2, 028 (80) 2, 785
(96)
1, 415 (49) 2, 465
(94)
2, 343 (90) 2, 207
(92)
Positive 503 (20) 1, 464 (58) 509 (20) 105 (4) 1, 475 (51) 146 (6) 268 (10) 182 (8)
*Excluding missing cases. Percentages cited in parentheses
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Table 3 CSC marker associations with clinical characteristics
ER POSITIVE ER NEGATIVE
Variable CD44+CD24-/low ALDH1A1 ALDH1A3 ITGA6 CD44+CD24-/low ALDH1A1 ALDH1A3 ITGA6
Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive
Morphology Ductal 1, 030
(73)
241 (81) 1, 357
(73)
38 (83) 1, 242
(73)
52 (75) 1, 116
(74)
41 (71) 369 (88) 125 (83) 491 (85) 45 (90) 434 (85) 60 (90) 373 (86) 83 (85)
Lobular 246 (17) 34 (11) 315 (17) 3 (7) 277 (16) 11 (16) 241 (16) 11 (19) 20 (5) 6 (4) 32 (5) 0 (0) 25 (5) 3 (4) 23 (5) 4 (4)
Other 140 (10) 23 (8) 188 (10) 5 (11) 176 (10) 6 (9) 142 (9) 6 (10) 32 (8) 19 (13) 58 (10) 5 (10) 52 (10) 4 (6) 37 (9) 11 (11)
P-value 0.012 0.172 0.892 0.803 0.169 0.238* 0.625* 0.645*
Grade 1 283 (23) 78 (33) 402 (25) 3 (11) 356 (25) 10 (19) 304 (24) 10 (26) 23 (6) 1 (1) 32 (6) 0 (0) 29 (7) 1 (2) 22 (6) 2 (3)
2 684 (56) 112 (47) 873 (55) 13 (46) 787 (55) 28 (53) 700 (55) 20 (51) 103 (28) 28 (23) 145 (29) 7 (21) 119 (27) 11 (24) 109 (29) 15 (19)
3 251 (21) 49 (21) 315 (20) 12 (43) 297 (21) 15 (28) 260 (21) 9 (23) 242 (66) 93 (76) 321 (64) 27 (79) 295 (67) 33 (73) 242 (65) 60 (78)
P-value 0.006 0.012* 0.335 0.874 0.012* 0.164* 0.538* 0.086*
Node status Negative 783 (60) 184 (68) 1064 (61) 23 (53) 972 (62) 41 (63) 859 (62) 34 (63) 203 (51) 84 (64) 310 (57) 19 (41) 268 (56) 34 (54) 206 (52) 55 (62)
Positive 533 (40) 86 (32) 669 (39) 20 (47) 602 (38) 24 (37) 528 (38) 20 (37) 195 (49) 48 (36) 231 (43) 27 (59) 207 (44) 29 (46) 194 (48) 34 (38)
P-value 0.008 0.293 0.830 0.878 0.012 0.036 0.712 0.078
Tumour size < 2 cm 788 (58) 182 (64) 1050 (59) 22 (49) 964 (59) 37 (55) 842 (59) 30 (52) 176 (44) 61 (43) 236 (43) 23 (48) 208 (43) 23 (37) 167 (41) 38 (44)
2 to 4.9
cm
545 (40) 88 (31) 695 (39) 22 (49) 628 (38) 28 (42) 551 (38) 27 (47) 208 (52) 74 (52) 289 (53) 23 (48) 259 (54) 36 (58) 225 (55) 45 (52)
≥5 cm 33 (2) 13 (5) 50 (3) 1 (2) 44 (3) 2 (3) 44 (3) 1 (2) 14 (4) 6 (4) 24 (4) 2 (4) 16 (3) 3 (5) 20 (5) 3 (3)
P-value 0.005 0.362* 0.747* 0.469* 0.916 0.777* 0.519* 0.821*
*Fisher’s exact test. Percentages are cited in parentheses.
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Table 4 CSC marker associations with molecular subtype and Ki67
ER POSITIVE ER NEGATIVE
Variable CD44+CD24-/low ALDH1A1 ALDH1A3 ITGA6 CD44+CD24-/low ALDH1A1 ALDH1A3 ITGA6
Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive
Molecular
subtype
Luminal
1a
1050 (83) 205 (75) 1, 331
(81)
28 (72) 1, 232
(81)
40 (59) 1, 045
(80)
41 (82) 60 (17) 9 (7) 75 (16) 2 (4) 71 (17) 2 (4) 62 (17) 8 (10)
Other 219 (17) 69 (25) 307 (19) 11 (28) 283 (19) 28 (41) 257 (20) 9 (18) 292 (83) 120 (93) 408 (84) 43 (96) 359 (83) 54 (96) 294 (83) 69 (90)
P-value 0.002 0.136 < 0.001 0.761 0.005 0.046* 0.009* 0.129
Luminal
1b
96 (8) 49 (18) 156 (10) 6 (15) 152 (10) 11 (16) 128 (10) 4 (8) 12 (3) 5 (4) 17 (4) 2 (4) 15 (3) 2 (4) 8 (2) 5 (6)
Other 1173 (92) 225 (82) 1482 (90) 33 (85) 1363 (90) 57 (84) 1174 (90) 46 (92) 340 (97) 124 (96) 466 (96) 43 (96) 415 (97) 54 (96) 348 (98) 72 (94)
P-value < 0.001 0.221 0.103 0.812* 0.806 0.672* 1.000* 0.062*
Luminal
2
123 (10) 20 (7) 151 (9) 5 (13) 131 (9) 17 (25) 129 (10) 5 (10) 13 (4) 3 (2) 16 (3) 2 (4) 14 (3) 2 (4) 16 (4) 1 (1)
Other 1, 146
(90)
254 (93) 1, 487
(91)
34 (87) 1, 384
(91)
51 (75) 1, 173
(90)
45 (90) 339 (96) 126 (98) 467 (97) 43 (96) 416 (97) 54 (96) 340 (96) 76 (99)
P-value 0.215 0.444 < 0.001 0.983 0.576* 0.660* 0.705* 0.329*
HER2 NA NA NA NA 81 (23) 14 (11) 86 (18) 17 (38) 83 (19) 14 (25) 76 (21) 12 (16)
Other 271 (77) 115 (89) 397 (82) 28 (62) 347 (81) 42 (75) 280 (79) 65 (84)
P-value 0.003 0.001 0.316 0.254
CBP NA NA NA NA 118 (34) 68 (53) 180 (37) 18 (40) 164 (38) 23 (41) 122 (34) 35 (45)
Other 234 (66) 61 (47) 303 (63) 27 (60) 266 (62) 33 (59) 234 (66) 42 (55)
P-value < 0.001 0.717 0.671 0.064
5NP NA NA NA NA 68 (19) 30 (23) 109 (23) 4 (9) 83 (19) 13 (23) 72 (20) 16 (21)
Other 284 (81) 99 (77) 374 (77) 41 (91) 347 (81) 43 (77) 284 (80) 61 (79)
P-value 0.342 0.035* 0.489 0.913
Ki67 Negative 1, 037
(77)
220 (77) 1, 370
(78)
27 (66) 1, 243
(78)
41 (61) 1, 088
(78)
37 (70) 196 (50) 52 (37) 262 (49) 13 (27) 232 (48) 23 (39) 200 (50) 30 (34)
Positive 305 (23) 65 (23) 386 (22) 14 (34) 360 (22) 26 (39) 308 (22) 16 (30) 197 (50) 90 (63) 276 (51) 36 (73) 255 (52) 36 (61) 198 (50) 58 (66)
P-value 0.977 0.064 0.002 0.163 0.007 0.003 0.208 0.006
*Fisher’s exact test. Percentages cited in parentheses
A
li
et
al.Breast
Cancer
Research
2011,13:R118
http://breast-cancer-research.com
/content/13/6/R118
Page
9
of
15
by molecular subtype is illustrated as a heatmap in Figure
3. Both CD44+CD24-/low and ALDH1A3 were negatively
associated with the luminal 1a subtype in both ER+ and
ER- disease. The luminal subtypes in the ER- subgroup
are ER-, PR+ tumours, of which there were 128. In ER-
disease ALDH1A1 was also negatively associated with the
luminal 1a subtype. Within ER- disease, we also found
CD44+CD24-/low to be associated with the CBP (basal)
subtype consistent with previous reports [12]. There was
a strong association between ALDH1A1 positivity and
the HER2 subtype in ER- disease with 38% of ALDH1A1
positive tumours being of the HER2 subtype compared
to 18% of ALDH1A1 negative cases (P = 0.001).
CSC markers were significantly associated with higher
proliferation measured by Ki67 labelling (Table 4).
ALDH1A3 positivity was associated with high Ki67
expression in ER+ disease, with 39% of ALDH1A3 posi-
tive cases having a Ki67 fraction of > 10% compared to
22% of ALDH1A3 negative cases (P = 0.002). In ER- dis-
ease, all CSC markers except ALDH1A3 were signifi-
cantly associated with > 10% Ki67 staining. This
relationship was strongest amongst ALDH1A1 positive
tumours where 73% of positive cases were also Ki67
positive whereas just 51% of negative cases were Ki67
positive (P = 0.003). Associations with clinical and mole-
cular characteristics for non-CSC markers (CD44-CD24
+, CD44+CD24+, stromal ALDH1A1, stromal
ALDH1A3) are detailed in Additional files 4 and 5.
CSC markers predict poor outcome in ER- disease
There were 1, 127 cases with complete data for all rele-
vant clinical variables and all IHC markers of a potential
4, 125 (27%). The median follow-up time was 8.54 years
with a total of 740 deaths of which 563 were deaths
from breast cancer. There were 507 deaths from breast
cancer when follow-up was restricted to 10 years.
Further details of the characteristics of the study cohort
can be found in Table 1.
On univariate analysis, CSC markers showed distinct
associations with survival and were more often
associated with outcome in ER- disease (Additional files
6 and 7). The CD44+CD24-/low phenotype was not sig-
nificantly associated with survival. Although ALDH1A1
was associated with poor outcome in both ER+ (HR 2.5,
95% CI 1.1 to 5.6, P = 0.027) and ER- disease (HR 2.4,
95% CI 1.4 to 4.1, P = 0.002) when complete data were
analysed, analysis of imputed data only reproduced the
association within ER- disease (HR 1.9, 95% CI 1.1 to
3.2, P = 0.022) and not in ER+ cases (HR 1.6, 95% CI
0.73 to 3.6, P = 0.233). ALDH1A3 was significantly asso-
ciated with survival within the ER- subgroup in both
complete (HR 1.8, 95% CI 1.1 to 3.1, P = 0.026) and
imputed (HR 1.7, 95% CI 1.1 to 2.9, P = 0.032) datasets.
Similarly, ITGA6 was associated with poorer survival in
ER- disease only. This association was time-dependent
in both the complete and imputed data with the
extended Cox-model showing that the hazard associated
with ITGA6 positivity fell over time. The Total CSC
score, representing a composite measure of all four CSC
markers, also showed an association with poorer survival
restricted to ER- disease and in the imputed dataset this
effect was time-dependent with a reduction in hazard
over time.
On multivariate analysis both ITGA6 and the Total
CSC composite score retained independent prognostic
value in ER- disease (Table 5 and Figure 4). Multivariate
analyses were restricted to CSC markers, which were
associated with outcome on univariate analysis.
ALDH1A1 showed independent prognostic value in ER-
disease in CCA only. This effect was not reproduced
when imputed data were analysed. ALDH1A3 was not
significantly associated with outcome on multivariate
analysis. As observed in univariate analyses, ITGA6
showed a time-dependent prognostic effect in both
complete (HR 7.5, 95% CI 2.6 to 21.6, P < 0.001; T 0.18
95% CI 0.06 to 0.54, P = 0.002) and imputed (HR 2.8,
95% CI 1.2 to 6.3, P = 0.013; T 0.50, 95% CI 0.24 to 1.0,
P = 0.055) datasets (CCA five-year BCSS adjusted for
tumour size, grade and node status: ITGA6 negative =
87%; ITGA6 positive = 77%). In CCA the Total CSC
ALDH1A1
ITGA6
ALDH1A3
CD44+/CD24Ͳ
Luminal1a Luminal1b Luminal2 HER2 CBP 5NP
Figure 3 Heatmap of CSC marker expression across breast cancer molecular subtypes. Heatmap illustrating the unclustered distribution of
cases from a single randomly selected imputed dataset across molecular subtypes defined by a five-marker IHC classifier. CSC markers arranged
by average linkage clustering.
Ali et al. Breast Cancer Research 2011, 13:R118
http://breast-cancer-research.com/content/13/6/R118
Page 10 of 15
variable was best modelled by not allowing for time-
dependence. The Total CSCs composite score showed
independent prognostic significance in complete data
for ER- disease, conferring a 70% increased relative risk
of event. In imputed data, the Total CSCs score also
retained a significant association with survival for ER-
disease and in a model allowing for time-dependence
this effect diminished with time (HR 1.8, 95% CI 1.2 to
2.6, P = 0.002; T 0.71, 95% CI 0.51 to 0.99, P = 0.042).
The five-year BCSS estimates for complete data adjusted
for tumour size, grade and node status were Total CSCs
= 0, 88%; Total CSCs = 1, 77%; Total CSCs = 2, 84%;
Total CSCs = 3, 11%. Although for complete data the
adjusted five-year survival is higher for a Total CSC
score of 2 compared to 1, this was not reproduced in
imputed data according to hazard ratios from a Cox
0.0
0.2
0.4
0.6
0.8
1.0
0 2 4 6 8 10
Years after diagnosis
ITGA6 - ITGA6 +
0.0
0.2
0.4
0.6
0.8
1.0
0 2 4 6 8 10
Years after diagnosis
Total CSCs 0 Total CSCs 1
Total CSCs 2 Total CSCs 3-4
A B
Figure 4 Kaplan-Meier survival plots of ITGA6 and Total CSC expression in ER- cases for BCSS. A. ITGA6 expression as a dichotomised
variable (zero- to two-year follow-up, log-rank P = 0.0016; n (events): ITGA6- = 309 (14), ITGA6+ = 52 (8)). B. Total CSC composite score (zero- to
four-year follow-up, log-rank P = 0.0173; n (events): CSC 0 = 164 (25), CSC 1 = 84 (22), CSC 2 = 19 (5), CSC 3 to 4 = 7 (4)).
Table 5 Multivariate survival analyses of ER negative cases for ALDH1A1, ITGA6 and Total CSC score
Variable Complete case analysis Multiple imputation (M = 50)
n HR (95% CI) P T (95% CI) P n HR (95% CI) P T (95% CI) P
Grade 481 3.6 (1.3 to 9.7) 0.011 0.32 (0.16 to 0.61) 0.001 1, 070 3.9 (1.8 to 8.3) < 0.001 0.42 (0.25 to 0.68) < 0.001
Node status 4.1 (2.6 to 6.3) < 0.001 NA 2.8 (2.1 to 3.9) < 0.001 NA
Tumour size * NA 1.5 (1.1 to 1.9) 0.002 NA
PR + 0.25 (0.13 to 0.50) < 0.001 NA 0.16 (0.03 to 0.69) 0.015 2.1 (0.78 to 5.4) 0.146
HER2+ * NA 1.4 (0.99 to 2.0) 0.060 NA
ALDH1A1 + 2.3 (1.3 to 4.0) 0.004 NA 1.4 (0.83 to 2.5) 0.191 NA
Grade 401 3.0 (0.99 to 9.0) 0.052 0.39 (0.18 to 0.82) 0.013 1, 070 4.2 (2.0 to 8.9) < 0.001 0.40 (0.24 to 0.64) < 0.001
Node status 4.2 (2.6 to 6.7) < 0.001 NA 2.9 (2.1 to 4.0) < 0.001 NA
Tumour size * NA 1.5 (1.1 to 1.9) 0.003 NA
PR + 0.23 (0.11 to 0.49) < 0.001 NA 0.42 (0.26 to 0.69) 0.001 NA
HER2+ * NA 1.4 (1.0 to 2.0) 0.034 NA
ITGA6 + 7.5 (2.6 to 21.6) < 0.001 0.18 (0.06 to 0.54) 0.002 2.8 (1.2 to 6.3) 0.013 0.50 (0.24 to 1.0) 0.055
Grade 298 3.8 (1.1 to 13.0) 0.036 0.30 (0.13 to 0.68) 0.004 1, 070 4.0 (1.8 to 8.5) < 0.001 0.41 (0.25 to 0.67) < 0.001
Node status 4.2 (2.4 to 7.4) < 0.001 NA 2.9 (2.1 to 4.0) < 0.001 NA
Tumour size * NA 1.5 (1.1 to 1.9) 0.003 NA
PR + 0.15 (0.05 to 0.44) < 0.001 NA 0.43 (0.26 to 0.70) 0.001 NA
HER2 + * NA 1.4 (1.0 to 2.0) 0.037 NA
Endocrine therapy 1.7 (0.98 to 2.9) 0.057 NA * NA
Total CSCs (0-3) 1.7 (1.3 to 2.4) < 0.001 NA 1.8 (1.2 to 2.6) 0.002 0.71 (0.51 to 0.99) 0.042
*Covariate dropped from final model. Grade, tumour size and Total CSCs modelled as continuous variables.
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proportional-hazards model where estimates of hazard
increased successively with higher Total CSCs scores
(data not shown). In order to investigate the relationship
with survival time for ITGA6 and the Total CSCs score,
follow-up time was divided into four periods (Table 6).
Period-specific survival analyses showed that for ITGA6
adverse outcome associated with positivity was restricted
to the first two years of follow-up, after which ITGA6
expression was not significantly associated with survival.
Similarly, for the Total CSCs score unfavourable prog-
nosis was restricted to the first four years after which
there was no significant association with survival.
Discussion
The CSC hypothesis holds that CSCs are solely respon-
sible for tumour recurrence and metastasis [4]. The
existence of CSCs in solid tumours was first demon-
strated in breast cancer in 2003; since then other studies
have also shown that a CSC population can be isolated
from primary breast tumours [1-3]. The idea that CSCs
are resistant to chemo- and radiotherapy has also been
supported by some studies [31-33]. These findings are
potentially of profound clinical importance and many
attempts to understand their clinical relevance have
been made. However, despite these efforts, the signifi-
cance of CSCs remains uncertain and many questions
persist. We have attempted to establish the clinical rele-
vance of CSCs in breast cancer by using IHC to assay
for putative CSC markers in a large cohort of primary
breast tumours in TMAs. We find that CSC markers
show distinct patterns of expression and association
with clinical and molecular features. We also show that
the prognostic significance of CSC markers is largely
restricted to ER- disease and that the most robust pre-
dictor of outcome is a composite score representing
expression of all four markers investigated. We show
that this score is the most powerful predictor of out-
come and an independent prognostic factor in ER-
disease.
Our study has some potential limitations. First, since
putative CSCs were originally identified using flow cyto-
metry we have assumed that this assay can be reason-
ably translated into an IHC based equivalent. Although
we would expect these modalities to identify a popula-
tion with a high degree of overlap, it is probable that
there will be some discordance. Second, we have used
TMAs to detect a subpopulation of cells of reputed
scarcity and as a result there is likely to be some sam-
pling error. However, we have attempted to mitigate
this effect by using a very large study cohort which has
also enabled us to address important questions, espe-
cially those related to subtype, with statistical robust-
ness. Finally, our analyses should be considered
exploratory. Validation studies using identical methodol-
ogy in independent cohorts are necessary before defini-
tive conclusions can be drawn. Analyses of associations
with clinical, molecular and outcome data where zero
was used as a cut-point for dichotomisation are pre-
sented in Additional files 8, 9, 10 and 11. Most reported
analyses are reproduced in these data, including the
independent prognostic value of the ‘Total CSC’ score
in the ER- subgroup. Although we find a small reduc-
tion in the hazard associated with CSC-positive cases
treated with adjuvant chemotherapy compared to those
who did not receive chemotherapy (data not shown),
questions relating to the chemo-resistance of CSC-
enriched tumours are best addressed in the context of
randomised clinical trials.
The CD44+CD24-/low phenotype was the first marker
described to enrich for breast CSCs [1]. This prompted
several attempts to characterise CD44+CD24-/low cells in
primary breast carcinomas. The prevalence of CD44
+CD24-/low cells has been shown to be associated with
the basal-like subtype [12,14], to favour distant metasta-
sis [34] and to be inversely associated with lymph node
status [13]. An association with survival has been
demonstrated by one study [15] and gene signatures
derived from CD44+ primary breast cancer cells and
CD44+CD24- breast cancer cells (from xenografts or
pleural effusions) have also been shown to correlate
with outcome [35,36]. We also found that tumours
enriched for the CD44+CD24-/low phenotype were asso-
ciated with the basal-like subtype and with negative
lymph node status. In addition, we found that CD44
+CD24-/low tumours were associated with the luminal 1b
subtype which, like basal-like tumours, is a subtype
defined by basal cytokeratin expression. However, we
did not find an association with survival.
Utilising the ALDEFLUOR assay, Ginestier et al. were
able to use high aldehyde dehydrogenase activity as a
basis for the enrichment of breast CSCs [3]. The group
also found ALDH1A1 to be an independent prognostic
Table 6 Adjusted period-specific hazard ratios (95% CI) for ITGA6 and Total CSC
Marker Follow-up (years)
0 to 2 P-value 2 to 4 P-value 4 to 6 P-value 6 to 10 P-value
ITGA6 2.4 (1.2 to 5.0) 0.019 1.4 (0.72 to 2.7) 0.329 0.60 (0.17 to 2.1) 0.429 0.68 (0.15 to 3.1) 0.612
Total CSCs 1.6 (1.1 to 2.3) 0.007 1.4 (1.0 to 1.9) 0.050 1.0 (0.60 to 1.7) 0.994 0.86 (0.43 to 1.7) 0.666
Adjusted for lymph node status, grade and tumour size. Analyses are of imputed data.
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factor when detected by IHC in primary breast carcino-
mas [3]. However, subsequent studies have not upheld
the prognostic significance of ALDH1A1 [16,17].
Despite this and in keeping with the CSC hypothesis,
ALDH1A1 has been found to predict response to che-
motherapy [37]. We found that ALDH1A1 was an inde-
pendent prognostic factor in ER- disease by CCA but
that this finding was not reproduced when imputed data
were analysed. Since missingness of data tends to be
correlated across variables, estimates from CCA can be
biased [26,27]. MI adjusts for this form of selection bias;
hence, we consider estimates derived from MI more
reliable than those from CCA. Our findings, coupled
with those of other studies, imply that ALDH1A1 alone
may not be a robust prognostic factor in breast cancer.
The assumption that ALDEFLUOR positivity of
tumour cells correlates with ALDH1A1 expression by
IHC has been questioned. Marcato et al. investigated
which isoform of the aldehyde dehydrogenase family
was most responsible for ALDEFLUOR positivity and
found ALDH1A3 rather than ALDH1A1 to be the basis
of ALDEFLUOR activity [5].
Although we found ALDH1A1 and ALDH1A3 to be
positively correlated, the relationship was not strong
(ER- cases, Spearman’s rho = 0.19, P < 0.0001) and
many cases showed discordant expression. We found
ALDH1A3 to be significantly associated with survival in
ER- disease on univariate analysis but this association
was lost after adjustment for known prognostic factors
in multivariate analysis.
ITGA6 expression has been linked to mammary stem
cell biology in different ways. It has been used as a mar-
ker of murine mammary stem cells [5,6] and of tumori-
genic cells of the MCF-7 breast cancer cell-line [7]. Pece
et al. found ITGA6 to be highly expressed by normal
human mammary stem cells and also showed that
ITGA6 expression correlated with tumour grade [2].
Although we did not find a significant association
between ITGA6 expression and higher tumour grade,
there is a trend towards this in the ER- subgroup.
ITGA6 expression has previously been shown to predict
poor outcome in breast cancer [38]. We found ITGA6
to be an independent prognostic factor in ER- disease
albeit restricted to the first two years of follow-up, after
which ITGA6 expression was not associated with
survival.
There is no highly specific marker for breast CSCs,
rather the markers investigated in this study enrich
tumour cell subpopulations for CSCs. We found a weak
to moderate correlation between CSC markers, implying
that different populations defined by these markers have
some overlap but that most cells do not express these
markers concurrently.
The idea of combining markers to increase the purity
of subpopulations for CSCs was utilised by Ginestier et
al. who showed that the combination of CD44+CD24-/
low and ALDEFLUOR activity enabled the isolation of
cells able to form tumours in NOD/SCID mice from as
few as 20 cells, compared to 500 cells when sorted by
ALDEFLUOR activity alone [3]. Based on this finding,
Neumeister et al. set out to establish the significance of
combined CSC marker expression by investigating the
expression of CD44 and ALDH1A1 in a cohort of 639
primary breast tumours [17]. They found no association
with survival when they analysed the markers separately,
but found the combination of the two markers to be an
independent predictor of outcome [17]. Along these
lines, we generated a score representing the sum of the
dichotomised scores for all four markers. We found that
this score was an independent prognostic factor in ER-
disease.
Conclusions
In summary, we have investigated the expression of
putative CSC markers in a large cohort of primary
breast carcinomas, treating ER+ and ER- tumours as
distinct entities. We found that the patterns of associa-
tion with clinical and molecular characteristics are dif-
ferent between CSC markers but that all markers were
strongly associated with negative ER status. CSC mar-
kers did not carry significant prognostic value in ER+
tumours; therefore, additional markers enabling IHC
quantification of CSCs in ER+ tumours (75 to 80% of all
breast cancers) are required. In ER- disease, although
only ITGA6 retained independent prognostic signifi-
cance, a composite score representing expression of all
four markers was the most powerful predictor of out-
come. Based on our findings and in the absence of more
specific CSC markers, we propose that it may be neces-
sary to utilise a panel of CSC markers in order to effec-
tively translate knowledge of CSCs into patient benefit.
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